First Hawaiian Bank Purchases 2,150 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

First Hawaiian Bank lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 21.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,243 shares of the company’s stock after acquiring an additional 2,150 shares during the period. First Hawaiian Bank’s holdings in Neurocrine Biosciences were worth $1,671,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. State Street Corp increased its holdings in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares during the period. Renaissance Technologies LLC raised its holdings in Neurocrine Biosciences by 9.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after acquiring an additional 216,500 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock valued at $213,773,000 after acquiring an additional 39,610 shares during the period. AQR Capital Management LLC grew its holdings in shares of Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares in the last quarter. Finally, Braidwell LP increased its position in shares of Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after purchasing an additional 158,665 shares during the period. 92.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Wedbush restated an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Raymond James reiterated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Piper Sandler restated an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.81.

Insider Buying and Selling

In other news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the sale, the insider now directly owns 2,507 shares of the company’s stock, valued at $346,216.70. This represents a 9.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,694 shares of company stock valued at $479,230 over the last quarter. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $138.71 on Thursday. The firm has a market cap of $14.04 billion, a price-to-earnings ratio of 37.19 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a 50 day moving average price of $128.95 and a two-hundred day moving average price of $130.85.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.